In The News
CNBC Fast Money: Altimmune CEO on what’s next for its experimental obesity drug
December 3, 2024
Source
CNBC Fast Money
Pemvidutide linked to 'rapid and potent' reduction in liver fat in MASLD at 12 weeks
August 6, 2024
Source
Healio
Pemvidutide seen to lower liver fat in MASLD patients in Phase 1 trial
August 5, 2024
Source
Liver Disease News
GLP-1/glucagon receptor agonist shows promise in liver disease
August 2, 2024
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
July 25, 2024
Source
Journal Of Hepatology
Go to article 964.1 KB
Altimmune says ‘double G’ drug has even better lean mass preservation data in obesity trial update
June 24, 2024
Source
Endpoints
Altimmune Targets Obesity Market With Weight-Loss Drug That Preserves Lean Muscle Mass
June 24, 2024
Source
BioSpace
Beyond Ozempic: New GLP-1 drugs promise weight loss and health benefits
June 23, 2024
Source
NBC
Altimmune touts 'best-in-class' lean mass results for weight loss therapy in quest to outdo big time competitors
June 23, 2024
Source
FierceBiotech
Measuring Muscle Loss in the ‘Wild West’ of Weight Loss Drugs
June 10, 2024
Source
BioSpace
Precision Medicine for Obesity: Targeting a Multifactorial Condition
June 5, 2024
Source
Inside Precision Medicine
What’s Next for Obesity Therapeutics? Higher Quality Weight Loss
April 29, 2024
Source
BioSpace
Looking for Attractive Gains in the Weight Loss Space
April 21, 2024
Source
TheStreet Pro
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
April 20, 2024
Source
The Motley Fool
A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug
March 29, 2024
Source
Business Insider
Altimmune boasts of diff erentiated obesity option
March 28, 2024
Source
The Pharma Letter
Download PDF 83.1 KB
Altimmune Axes Hepatitis B Program After Phase II Failure, Focuses on Obesity and MASH
March 28, 2024
Source
BioSpace
Altimmune says weight loss drug minimized muscle loss in trial results, which may set it apart
March 27, 2024
Source
CNBC
Altimmune cuts hepatitis B program, reports more data on its GLP-1/glucagon for obesity and MASH
March 27, 2024
Source
Endpoints
Download PDF 197.4 KB
Altimmune Obesity Drug Sheds Fat With Less Muscle Loss in Trial
March 27, 2024
Source
Bloomberg
A Novo Nordisk competitor teased a weight loss drug that minimizes muscle loss seen in other drugs
March 27, 2024
Source
Quartz
What To Know About Pemvidutide—Altimmune Says Weight Loss Drug Minimized Muscle Mass Loss In Trial
March 27, 2024
Source
Forbes
Altimmune flexes muscle-sparing, adipose tissue-targeted weight loss data
March 27, 2024
Source
FirstWord Pharma
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
February 14, 2024
Source
Scrip
Altimmune open to partnerships, deals with drugmakers, says CEO
December 5, 2023
Source
Reuters
Altimmune’s fate turns around after longer look at obesity trial
December 1, 2023
Source
Endpoints
Altimmune Joins Weight-Loss Race with Phase II Win, Stock Jumps on News
December 1, 2023
Source
BioSpace
What a pair of Phase II obesity results could mean for Altimmune, Pfizer
December 1, 2023
Source
BioCentury
Altimmune’s stock soars more than 40% after biopharma company says trial of obesity drug led to weight loss
November 30, 2023
Source
MarketWatch
Altimmune Jumps 66% After Positive Results for Its Obesity Drug
November 30, 2023
Source
Bloomberg
New 'Twincretin' Pemvidutide: Another Option for Obesity
October 16, 2023
Source
Medscape
Biopharmas focus on glucagon, amylin and other targets beyond GLP-1s
October 4, 2023
Source
BioWorld
Development, investments, partnerships climb, but safety is key
October 3, 2023
Source
BioWorld
With high societal costs, a burgeoning market size, developers seek reimbursement for weight-loss meds
October 2, 2023
Source
BioWorld
Merck And Altimmune Vie To Be Leaders In NAFLD And NASH
June 15, 2023
Source
Scrip
Altimmune sees phase 1 success in tricky NASH indication with GLP-1 agonist
September 14, 2022
Source
FierceBiotech
Effects of ALT‑801, a GLP‑1 and glucagon receptor dual agonist, in a translational mouse model of non‑alcoholic steatohepatitis
April 23, 2022
Source
Scientific Reports
Download PDF 9.7 MB
Potential New Obesity Drug Heads to Phase II Trials
January 31, 2022
Source
BioSpace
